The anti-thrombotic effects of statins.

Suppr

超能文献

作者信息

Kearney D, Fitzgerald D

出版信息

J Am Coll Cardiol. 1999 Apr;33(5):1305-7. doi: 10.1016/s0735-1097(99)00019-4.

DOI:10.1016/s0735-1097(99)00019-4

PMID:10193731

Abstract

摘要

相似文献

The anti-thrombotic effects of statins.

J Am Coll Cardiol. 1999 Apr;33(5):1305-7. doi: 10.1016/s0735-1097(99)00019-4.

Statins and aortic stenosis in the context of ratio of low- to high-density lipoprotein cholesterol.

J Am Coll Cardiol. 2007 Jul 17;50(3):289-90; author reply 290. doi: 10.1016/j.jacc.2007.02.072. Epub 2007 Jun 29.

Cholesterol--frequently asked questions.

Aust Fam Physician. 2006 Aug;35(8):595-6.

Aggressive lipid reduction provides additional clinical benefit.

Am J Manag Care. 2002 Jul;Suppl Symposium Reporter:1, 4.

[Lipid lowering by rosuvastatin: how do statins differ?].

Dtsch Med Wochenschr. 2015 Mar;140(5):313. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3.

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.

BMC Fam Pract. 2003 Dec 1;4:18. doi: 10.1186/1471-2296-4-18.

Stricter cholesterol guidelines broaden indications for the 'statin' drugs.

Medsurg Nurs. 2003 Feb;12(1):51-7.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003.

Lipid management with statins. The lower the better?

Z Kardiol. 2004 Jan;93(1):4-9. doi: 10.1007/s00392-004-1023-y.

Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?

Curr Atheroscler Rep. 2013 Jan;15(1):290. doi: 10.1007/s11883-012-0290-8.

引用本文的文献

Statins can benefit patients with primary membranous nephropathy on venous thromboembolism.

Ren Fail. 2021 Dec;43(1):302-306. doi: 10.1080/0886022X.2021.1879853.

The role of statins in neurosurgery.

Neurosurg Rev. 2010 Jul;33(3):259-70; discussion 270. doi: 10.1007/s10143-010-0259-4. Epub 2010 Apr 29.

Spectrum of pleiotropic effects of statins in heart failure.

Heart Fail Clin. 2008 Apr;4(2):153-61. doi: 10.1016/j.hfc.2008.01.007.

Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.

Br J Pharmacol. 2008 Mar;153(6):1281-7. doi: 10.1038/bjp.2008.19. Epub 2008 Feb 11.

HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Osteoporos Int. 2003 Jun;14(4):273-82. doi: 10.1007/s00198-002-1323-x. Epub 2003 May 8.

The role of dyslipidemia and statins in venous thromboembolism.

Curr Control Trials Cardiovasc Med. 2001;2(4):165-170. doi: 10.1186/cvm-2-4-165.

New developments in the treatment of low high-density lipoprotein cholesterol.

Curr Atheroscler Rep. 1999 Jul;1(1):24-30. doi: 10.1007/s11883-999-0046-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The anti-thrombotic effects of statins.

J Am Coll Cardiol. 1999 Apr;33(5):1305-7. doi: 10.1016/s0735-1097(99)00019-4.

Statins and aortic stenosis in the context of ratio of low- to high-density lipoprotein cholesterol.

J Am Coll Cardiol. 2007 Jul 17;50(3):289-90; author reply 290. doi: 10.1016/j.jacc.2007.02.072. Epub 2007 Jun 29.

Cholesterol--frequently asked questions.

Aust Fam Physician. 2006 Aug;35(8):595-6.

Aggressive lipid reduction provides additional clinical benefit.

Am J Manag Care. 2002 Jul;Suppl Symposium Reporter:1, 4.

[Lipid lowering by rosuvastatin: how do statins differ?].

Dtsch Med Wochenschr. 2015 Mar;140(5):313. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3.

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.

BMC Fam Pract. 2003 Dec 1;4:18. doi: 10.1186/1471-2296-4-18.

Stricter cholesterol guidelines broaden indications for the 'statin' drugs.

Medsurg Nurs. 2003 Feb;12(1):51-7.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003.

Lipid management with statins. The lower the better?

Z Kardiol. 2004 Jan;93(1):4-9. doi: 10.1007/s00392-004-1023-y.

Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?

Curr Atheroscler Rep. 2013 Jan;15(1):290. doi: 10.1007/s11883-012-0290-8.

引用本文的文献

Statins can benefit patients with primary membranous nephropathy on venous thromboembolism.

Ren Fail. 2021 Dec;43(1):302-306. doi: 10.1080/0886022X.2021.1879853.

The role of statins in neurosurgery.

Neurosurg Rev. 2010 Jul;33(3):259-70; discussion 270. doi: 10.1007/s10143-010-0259-4. Epub 2010 Apr 29.

Spectrum of pleiotropic effects of statins in heart failure.

Heart Fail Clin. 2008 Apr;4(2):153-61. doi: 10.1016/j.hfc.2008.01.007.

Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.

Br J Pharmacol. 2008 Mar;153(6):1281-7. doi: 10.1038/bjp.2008.19. Epub 2008 Feb 11.

HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Osteoporos Int. 2003 Jun;14(4):273-82. doi: 10.1007/s00198-002-1323-x. Epub 2003 May 8.

The role of dyslipidemia and statins in venous thromboembolism.

Curr Control Trials Cardiovasc Med. 2001;2(4):165-170. doi: 10.1186/cvm-2-4-165.

New developments in the treatment of low high-density lipoprotein cholesterol.

Curr Atheroscler Rep. 1999 Jul;1(1):24-30. doi: 10.1007/s11883-999-0046-2.